Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Apasia, Stamatoullas"'
Autor:
Romain-David Seban, Anna Schmitt, Aiping Chen, Guillaume Manson, Jean-Marc Schiano de Colella, Lawrence H. Schwartz, Olivier Casasnovas, Fatima-Zohra Mokrane, Laurent Dercle, Apasia Stamatoullas, Laetitia Vercellino, Roch Houot, Remy Dulery, Marie-Pierre Moles-Moreau, Hervé Ghesquières, Frederic Peyrade, Emmanuelle Nicolas-Virelizier, Mohamed Touati, Franck Morschhauser, Adrien Chauchet, Krimo Bouabdallah, Benedicte Deau-Fischer, Cécile Borel, Alain Delmer
Publikováno v:
Radiology. 295:651-661
Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances following immune therapy are not well known in patients with relapsed or refractory Hodgkin lymphoma (RRHL). Purpose To compare CT and PET/CT for prognostic value of ear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a61eb2081907387cd88b8734ab2afbc0
https://doi.org/10.1148/radiol.2020192056
https://doi.org/10.1148/radiol.2020192056
Autor:
Alain Delmer, Laurent Dercle, Guillaume Manson, Frederic Peyrade, Mohamed Touati, Romain-David Seban, Krimo Bouabdallah, Laetitia Vercellino, Aiping Chen, Adrien Chauchet, Roch Houot, Marie-Pierre Moles-Moreau, Anna Schmitt, Philippe Armand, Lawrence H. Schwartz, Cécile Borel, Emmanuelle Nicolas-Virelizier, Hervé Ghesquières, Remy Dulery, Franck Morschhauser, Benedicte Deau-Fischer, Apasia Stamatoullas, Jean-Marc Schiano de Colella, Fatima-Zohra Mokrane, Olivier Casasnovas
Publikováno v:
Journal of Nuclear Medicine. 61:649-654
Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients with relapsed or refractory classic Hodgkin lymphoma (HL). To date, no prognostic factor for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f46b6ae91944bae95cc704d78e28b63a
https://doi.org/10.2967/jnumed.119.232827
https://doi.org/10.2967/jnumed.119.232827
Autor:
Marie Maerevoet, Jm Schiano, Bénédicte Deau, Mg Silva, Apasia Stamatoullas, Roch Houot, Guillaume Manson, Pauline Brice, Laurent Dercle, Herve Ghesquieres, Carmelo Carlo-Stella, Juliette Bouteloup, Kamal Bouabdallah, Charles Herbaux, Florence Poizeau, E. Nicolas-Virelizier, M. de Charette, Chloe Antier
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2021, 48 (4), pp.1144-1153. ⟨10.1007/s00259-020-05015-2⟩
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 (4), pp.1144-1153. ⟨10.1007/s00259-020-05015-2⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2021, 48 (4), pp.1144-1153. ⟨10.1007/s00259-020-05015-2⟩
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 (4), pp.1144-1153. ⟨10.1007/s00259-020-05015-2⟩
International audience; Introduction - Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, the optimal duration of treatment and the risk of relapse after anti-PD1 disco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aefbc7b6b27abe5d67d08244dc41fdc2
https://hal.archives-ouvertes.fr/hal-02931653
https://hal.archives-ouvertes.fr/hal-02931653
Autor:
Fatima-Zohra, Mokrane, Aiping, Chen, Lawrence H, Schwartz, Franck, Morschhauser, Apasia, Stamatoullas, Jean-Marc, Schiano de Colella, Laetitia, Vercellino, Olivier, Casasnovas, Adrien, Chauchet, Alain, Delmer, Emmanuelle, Nicolas-Virelizier, Hervé, Ghesquières, Marie-Pierre, Moles-Moreau, Anna, Schmitt, Rémy, Duléry, Krimo, Bouabdallah, Cecile, Borel, Mohamed, Touati, Bénédicte, Deau-Fischer, Frédéric, Peyrade, Romain-David, Seban, Guillaume, Manson, Roch, Houot, Laurent, Dercle
Publikováno v:
Radiology. 295(3)
Background CT and fluorine 18 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bedbe24671432152202ae87b84c0f950
https://pubmed.ncbi.nlm.nih.gov/32293222
https://pubmed.ncbi.nlm.nih.gov/32293222
Autor:
Jean-Marc Schiano, Laurent Dercle, Juliette Bouteloup, Kamal Bouabdallah, Marie Maerevoet, Carmelo Carlo-Stella, Roch Houot, Maria Gomes da Silva, Pauline Brice, Charles Herbaux, Bénédicte Deau, Florence Poizeau, Guillaume Manson, Emmanuelle Nicolas-Virelizier, Chloe Antier, Herve Ghesquieres, Apasia Stamatoullas, M. de Charette
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 (5), pp.1699-1700. ⟨10.1007/s00259-021-05321-3⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2021, 48 (5), pp.1699-1700. ⟨10.1007/s00259-021-05321-3⟩
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 (5), pp.1699-1700. ⟨10.1007/s00259-021-05321-3⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2021, 48 (5), pp.1699-1700. ⟨10.1007/s00259-021-05321-3⟩
International audience; Introduction: Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, the optimal duration of treatment and the risk of relapse after anti-PD1 discon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b29740eea8951fefc00352fb2d6756b4
https://doi.org/10.1007/s00259-021-05321-3
https://doi.org/10.1007/s00259-021-05321-3
Autor:
Aiping, Chen, Fatima-Zohra, Mokrane, Lawrence H, Schwartz, Franck, Morschhauser, Apasia, Stamatoullas, Jean-Marc, Schiano de Colella, Laetitia, Vercellino, Olivier, Casasnovas, Adrien, Chauchet, Alain, Delmer, Emmanuelle, Nicolas-Virelizier, Hervé, Ghesquières, Marie-Pierre, Moles-Moreau, Anna, Schmitt, Rémy, Dulery, Krimo, Bouabdallah, Cecile, Borel, Mohamed, Touati, Benedicte, Deau-Fischer, Frédéric, Peyrade, Romain-David, Seban, Guillaume, Manson, Philippe, Armand, Roch, Houot, Laurent, Dercle
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(5)
Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients with relapsed or refractory classic Hodgkin lymphoma (HL). To date, no prognostic factor for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e76c7279127b6ea2d8e10e6df389a85a
https://pubmed.ncbi.nlm.nih.gov/31628220
https://pubmed.ncbi.nlm.nih.gov/31628220
Autor:
Pauline Brice, Apasia Stamatoullas, Fatima-Zohra Mokrane, Franck Morschhauser, Aiping Chen, Roch Houot, Guillaume Manson, Hervé Ghesquières, Laurent Dercle, Jean Marc Schiano de Colella, Olivier Casasnovas
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (6), pp.1391-1392. ⟨10.1007/s00259-019-04310-x⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (6), pp.1391-1392. ⟨10.1007/s00259-019-04310-x⟩
European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (6), pp.1391-1392. ⟨10.1007/s00259-019-04310-x⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (6), pp.1391-1392. ⟨10.1007/s00259-019-04310-x⟩
International audience; The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic chemotherapies and its use as a reference model for immune-modulatory regimens, which restores the immune system's anti-tumor capacity, is questioned
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d4defa8dee28f6676b68ca77d5f142
https://doi.org/10.1007/s00259-019-04310-x
https://doi.org/10.1007/s00259-019-04310-x
Autor:
Vincent Ribrag, Pauline Brice, Jean Gabarre, Gilles Salles, Apasia Stamatoullas, Gilbert M. Lenoir, Laurent Voillat, Marine Divine, Cecile Cazeneuve, Franck Morschhauser, Olivier Casasnovas, Serge Koscielny
Publikováno v:
Blood. 108:2266-2266
Hodgkin lymphoma is a highly curable malignancy, but treatment outcome might be influenced by some patient’s germline polymorphisms that determine anticancer agent metabolism. We prospectively collected peripheral blood lymphocytes from 313 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fe8a0b64299380647d3727b7b7abbae
https://doi.org/10.1182/blood.v108.11.2266.2266
https://doi.org/10.1182/blood.v108.11.2266.2266
Autor:
Dercle, Laurent1,2 laurent.dercle@gmail.com, Mokrane, Fatima-Zohra1,3, Schiano de Colella, Jean Marc4, Stamatoullas, Apasia5, Morschhauser, Franck6, Brice, Pauline7, Ghesquières, Hervé8, Casasnovas, Olivier9, Chen, Aiping10, Manson, Guillaume11,12, Houot, Roch11,12
Publikováno v:
European Journal of Nuclear Medicine & Molecular Imaging. Jun2019, Vol. 46 Issue 6, p1391-1392. 2p.